NanoKnife Investor Day Presentation: Revolutionizing Prostate Care

Published: 2025-01-08 11:43:09 ET ANGO

Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete

against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of ongoing litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Drive Portfolio Transformation

Exited and/or divested certain non-strategic businesses, reallocating resources into differentiated technologies, an expanded and robust R&D pipeline, and investing in clinical data generation while exploring new indications to drive growth opportunities.

Improve Financial Profile and Capital Structure

Through strategic business development efforts, we recapitalized our balance sheet and transformed our portfolio to drive future margin expansion and sustained profitable growth.

Pursue Larger, Faster Growing Markets

Significantly expanded the scope of our Med Tech portfolio through R&D, M&A, and clinical/regulatory initiatives by entering the mechanical thrombectomy market, capitalizing on the solid PAD market, and building on the under-penetrated prostate focal therapy market.

Med Tech Global TAM

$10 B

+233%

$3 B

FY 2021

FY 2024

A leading medical technology company driving sustained growth and profitability through its commitment to expanding treatment options, enhancing patient outcomes, and improving quality of life, with a strategic focus on combating cardiovascular disease and cancer.

Venous Thromboembolism (VTE)

$5.3B US TAM

Prostate Care

$2.7B Global TAM ($780M US)

Peripheral Artery Disease (PAD)

$760M US TAM

To Become

An innovative, versatile, hour-long prostate treatment*1,2

*Treatment time does not include patient prep, anesthesia initiation or recovery room time. 1-2 See reference page

Thermal, Radiation Free Ablation Technology

Clinical Outcomes Patients and Physicians Need

Building Momentum and Strong Commercial Viability

Proven Go-To Market Strategy For Developing New Markets

3 - See reference page

REV 01 GL/ON/PR/3126

*The NanoKnife System indications for use vary per region. Please refer to the indications for use for approved use per region

The most diagnosed male cancer in 112 countries, including the U.S.4

annual diagnoses5 worldwide

annual diagnoses in the U.S.

4-6 See reference page

Incidence projected to

Takes more healthy years from

double by 20404

men's lives than any other cancer 6

Aging populations

Increasing life expectancy

The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions.

-The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases

REV 01 GL/ON/PR/3126

Radical surgery or external beam radiation therapy

†

7-9 See reference page

† AngioDynamics Internal Estimates

REV 01 GL/ON/PR/3126

Between Their Quality of Life or Controlling Their Cancer

Of patients will avoid treatment, but this group will have more clinical progression, metastases, and androgen-deprivation therapy initiation when compared with patients who undergo definitive therapy10

5 years 50.2%

10 years 38.7%

15 years 33.7%

Active Surveillance

Definitive Treatment

Possibility of

Risk of serious long term

cancer progression

urological side effects

Erectile Dysfunction

Urinary Incontinence

Baseline 34%

Baseline 30%

1-year 85%

1-year 71%

Erectile Dysfunction

Urinary Incontinence

Baseline 32%

Baseline 31%

1-year 62%

1-year 39%

10-13 See reference page

REV 01 GL/ON/PR/3126

Low

Intermediate

High

Risk

Neoadjuvant ADT

30.2%

48.5%

79.1%

Treatment Failure*

9.7%

22.7%

42.9%

*at 8-year follow-up

Disclaimer

AngioDynamics Inc. published this content on January 08, 2025, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 08, 2025 at 16:42:04.630.